Prostate Cancer Diagnosis and Treatment

Initial Evaluation

A PSA level of 9.3 ng/mL indicates a significant risk of malignancy, and a prostate biopsy should be performed to rule out prostate cancer, as recommended by the National Comprehensive Cancer Network 1, 2
The National Comprehensive Cancer Network suggests that a PSA level of 9.3 ng/mL falls within the 4.0-10.0 ng/mL range, where approximately 1 in 3 men will have prostate cancer on biopsy 1
The American Urological Association indicates that the higher the PSA level, the more likely a man will be found to have prostate cancer if a biopsy is performed 3
A PSA level above 4.0 ng/mL warrants further evaluation with prostate biopsy, according to the National Comprehensive Cancer Network and the American Urological Association 4, 2
Before proceeding to biopsy, consider confirming the elevated PSA with a repeat test, as laboratory variability can range from 20-25%, as suggested by the American Urological Association 2

The National Comprehensive Cancer Network recommends transrectal ultrasound-guided prostate biopsy as the standard approach, typically taking 10-12 core samples 1
The American Urological Association suggests that digital rectal examination (DRE) should be performed in conjunction with PSA testing to improve overall cancer detection 2
PSA velocity (change over time) should be considered - a rise of ≥0.75 ng/mL per year in the PSA range of 4-10 ng/mL increases concern for cancer, as indicated by the American Urological Association 2

Treatment options depend on several factors, including Gleason score (tumor grade), clinical stage, patient's age and overall health, and patient preferences, as recommended by the National Comprehensive Cancer Network 5, 1
The American Urological Association suggests that radical prostatectomy is most appropriate for localized disease 5
The National Comprehensive Cancer Network indicates that PSA should become undetectable (<0.1 ng/mL) within one month after surgery 7

Radical Prostatectomy is a surgical removal of the prostate, most appropriate for localized disease, as recommended by the American Urological Association 6, 3, 5
Radiation Therapy, including external beam radiation or brachytherapy, can be used for localized or locally advanced disease, as suggested by the National Comprehensive Cancer Network 6, 3, 5
Active Surveillance is appropriate for low-risk, slow-growing cancers, involving regular PSA tests and physical examinations, as recommended by the National Comprehensive Cancer Network 3, 1
Androgen Deprivation Therapy (ADT) is a hormonal therapy that reduces testosterone levels, generally used for more advanced disease or in combination with radiation, as indicated by the American College of Radiology 7, 5

The American Urological Association suggests that bone scan is generally unnecessary if PSA <20.0 ng/mL unless there are symptoms suggesting bone involvement 5
CT or MRI may be considered for staging when PSA >20.0 ng/mL or when Gleason score ≥8, as recommended by the American Urological Association 5
Pelvic lymph node dissection may not be necessary if PSA <10.0 ng/mL and Gleason score ≤6, as indicated by the American Urological Association 5

Regular PSA monitoring is essential after definitive treatment, as recommended by the American College of Radiology 7
After radical prostatectomy, biochemical recurrence is defined as PSA ≥0.2 ng/mL with a confirmatory value ≥0.2 ng/mL, as indicated by the American Urological Association 5
Salvage radiation therapy should be offered to patients with PSA recurrence after radical prostatectomy when there is no evidence of distant metastatic disease, as recommended by the Journal of Clinical Oncology 8, 6
The effectiveness of salvage radiotherapy is greatest when administered at lower PSA levels, as suggested by the Journal of Clinical Oncology 6